The Mobile Insulin Dosing System (MIDS) is currently available for investigational use only.

In the study, the company assessed MIDS for long-acting insulin (LAI) dose adjustment, helping in appropriate titration adjustments and improving glycemic status.

Conducted for three weeks, the study showed that the mean blood glucose level of participants decreased on average by 18.2 mg/dL, while proportion of in-range blood glucose readings increased by 9% points from 64.2% to 73.2%.

The study has also demonstrated that the percentage of hyperglycemic events of participants decreased from 14.1% of readings to 3.2% of readings and recommended LAI dose increased by 18.7% from the initial dosage by the end of the study period.

Glooko CEO Rick Altinger said: “We are thrilled to see early clinical evidence show the positive impact the Glooko Mobile Insulin Dosing System can have on people with diabetes.

“Glooko’s mission has always been to improve clinical outcomes for people with diabetes by making diabetes management easier through digital tools.

“The potential for improving adherence – and thus improving outcomes and reducing costs – can be invaluable to people with diabetes on long-acting insulin globally.”

Image: Glooko’s mobile health app has improved glycemic control in people with type 2 diabetes in feasible study. Photo: courtesy of Stuart Miles /